echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Roche trastuzumab subcutaneous injection application for listing

    Roche trastuzumab subcutaneous injection application for listing

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 22, the CDE official website showed that Roche's application for the listing of trastuzumab subcutaneous injection was officially accepted by the NMPA.


    Trastuzumab subcutaneous injection is a compound preparation composed of Roche anti-Her2 monoclonal antibody trastuzumab and the recombinant human hyaluronidase PH20 (rHuPH20, a kind of endoglycosidase) developed by Halozyme based on the Enhanze technology platform.


    The advantage of Herceptin Hylecta is that the hyaluronidase in the preparation can temporarily reduce the viscosity of the intercellular substance and promote the rapid diffusion and absorption of trastuzumab, making it a ready-to-use preparation that can be used in 2-5 The administration is completed within minutes, while intravenous infusion of trastuzumab takes 30-90 minutes.


    The efficacy and safety of Herceptin Hylecta have been confirmed in 3 clinical studies on Her2-positive early breast cancer patients.


    The Phase III clinical study code-named HannaH compared subcutaneous injection of Herceptin Hylecta combined with chemotherapy vs.


    In the Phase III clinical study code-named SafeHER, the safety and tolerability of Herceptin Hylecta in the adjuvant treatment of Her2-positive breast cancer were consistent with the previous safety features of intravenous Herceptin, and no new safety signals were found.


    The study code-named PrefHER investigated the medication preference of patients.


    Trastuzumab subcutaneous injection provides a new treatment option for patients, and patients can choose treatment methods according to personal needs and preferences.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.